Ayvakit Now Available to Treat Adults With Indolent Systemic Mastocytosis
Adults with indolent systemic mastocytosis (SM) now have a medicine to treat their disease after the groundbreaking approval of Ayvakit® (avapritinib) by the US Food and Drug Administration (FDA). “Today’s approval of Ayvakit reflects more than a decade of collaboration and leadership in the field of SM, during which our team at Blueprint Medicines has…